Both drugs increase insulin sensitivity, triglyceride clearance, lipolysis (fat utilization for fuel) metabolic rate, and decrease appetites, fat storage, and digestion
***Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program
Because Retatrutide is a research peptide, ordering it is different from obtaining an approved medication for obesity, diabetes, or weight management
individual tolerability depends on genetic factors, dose titration speed, and gastrointestinal sensitivity rather than manufacturing source
DPP4 Gene Expression Reduction: Lowers the expression of the DPP-4 enzyme, helping to protect your natural GLP-1 from being broken down too quickly so it stays active in your body longer